Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.
Aberrant melanocortin signaling has been implicated in the pathogenesis of wasting in chronic kidney disease (CKD). Previously, we demonstrated that agouti-related peptide (AgRP), a melenocortin-4 receptor antagonist, reduced CKD-associated cachexia in CKD mice. Our previous studies with AgRP utilized dual energy X-ray (DXA) densitometry to assess the body composition in mice (Cheung W, Kuo HJ, Markison S, Chen C, Foster AC, Marks DL, Mak RH. J Am Soc Nephrol 18: 2517-2524, 2007; Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. J Clin Invest 115: 1659-1665, 2005). DXA is unable to differentiate water content in mice, and fluid retention in CKD may lead to an overestimate of lean mass. In this study, we employed quantitative magnetic resonance technique to evaluate body composition change following central administration of AgRP in a CKD mouse model. AgRP treatment improved energy expenditure, total body mass, fat mass, and lean body mass in CKD mouse. We also investigated the effect of CKD-associated cachexia on the signaling pathways leading to wasting in skeletal muscle, as well as whether these changes can be ameliorated by central administration of AgRP. AgRP treatment caused an overall decrease in proinflammatory cytokines, which may be one important mechanism of its effects. Muscle wasting in CKD may be due to the activation of proteolytic pathways as well as inhibition of myogenesis and muscle regeneration processes. Our results suggest that these aberrant pathological pathways leading to muscle wasting in CKD mice were ameliorated by central administration of AgRP.
Pediatric Nephrology, University of California, San Diego, California, USA.
Wai W
WW
Cheung
Robert H
RH
Mak
D054369:Agouti-Related Protein / Q000494:pharmacology*; D000818:Animals; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D002100:Cachexia / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D007249:Inflammation / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D053486:Melanocortins / Q000037:antagonists & inhibitors*; D051379:Mice; D008810:Mice, Inbred C57BL; D018908:Muscle Weakness / Q000378:metabolism / Q000517:prevention & control*; D009392:Nephrectomy / Q000009:adverse effects; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000209:etiology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D054369:Agouti-Related Protein; C515199:Agrp protein, mouse; D016207:Cytokines; C574273:MC4R protein, mouse; D053486:Melanocortins; D044105:Receptor, Melanocortin, Type 4